Stock NBIX NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
136.7 USD -2.12% Intraday chart for Neurocrine Biosciences, Inc. -2.85% +3.75%
May. 09 Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 CI
May. 08 Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,899 8,955 8,080 11,482 12,946 13,757 - -
Enterprise Value (EV) 1 9,279 8,472 7,704 10,363 11,397 11,760 10,962 10,109
P/E ratio 276 x 23 x 92.6 x 76.6 x 53.3 x 32.8 x 21.6 x 16 x
Yield - - - - - - - -
Capitalization / Revenue 12.6 x 8.56 x 7.13 x 7.71 x 6.86 x 6.19 x 5.41 x 4.65 x
EV / Revenue 11.8 x 8.1 x 6.8 x 6.96 x 6.04 x 5.29 x 4.31 x 3.42 x
EV / EBITDA 116 x 44.2 x 58.9 x 39.2 x 42.4 x 21.2 x 12.5 x 9.13 x
EV / FCF 67.6 x 38.9 x 33 x 32.1 x 31.5 x 20.3 x 14.4 x 10.7 x
FCF Yield 1.48% 2.57% 3.03% 3.12% 3.17% 4.92% 6.92% 9.33%
Price to Book 15.6 x 7.92 x 5.86 x 6.75 x 5.83 x 5.11 x 4.02 x 2.87 x
Nbr of stocks (in thousands) 92,094 93,429 94,867 96,134 98,252 100,637 - -
Reference price 2 107.5 95.85 85.17 119.4 131.8 136.7 136.7 136.7
Announcement Date 2/4/20 2/4/21 2/11/22 2/6/23 2/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 788.1 1,046 1,134 1,489 1,887 2,221 2,541 2,958
EBITDA 1 79.74 191.6 130.7 264.1 268.7 555.8 879.4 1,107
EBIT 1 72.3 163 102.5 249 250.9 579.7 834.4 1,117
Operating Margin 9.17% 15.58% 9.04% 16.73% 13.3% 26.1% 32.84% 37.76%
Earnings before Tax (EBT) 1 46.5 106.7 101.4 213.9 332.1 553.6 857.6 1,160
Net income 1 37 407.3 89.6 154.5 249.7 438.7 665.9 905.4
Net margin 4.69% 38.94% 7.9% 10.38% 13.23% 19.75% 26.21% 30.61%
EPS 2 0.3900 4.160 0.9200 1.560 2.470 4.168 6.338 8.563
Free Cash Flow 1 137.3 217.6 233.1 323 361.6 578.8 758.7 943.4
FCF margin 17.42% 20.81% 20.56% 21.7% 19.16% 26.06% 29.86% 31.89%
FCF Conversion (EBITDA) 172.2% 113.57% 178.35% 122.3% 134.56% 104.14% 86.27% 85.19%
FCF Conversion (Net income) 371.1% 53.42% 260.16% 209.06% 144.8% 131.94% 113.92% 104.2%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/4/20 2/4/21 2/11/22 2/6/23 2/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 312 310.6 378.2 387.9 412 420.4 452.7 498.8 515.2 515.3 547.1 567.8 586.8 578.3 608.8
EBITDA 1 -28.9 6.8 59 91.8 107.3 -109.2 78.7 144 155.2 105.5 145.9 158.5 136.3 - -
EBIT 1 -36.3 3.1 54.7 87.8 103.4 -114.2 73.6 141.2 150.3 99.3 144.7 161.9 169.7 151.3 174.2
Operating Margin -11.63% 1% 14.46% 22.63% 25.1% -27.16% 16.26% 28.31% 29.17% 19.27% 26.45% 28.51% 28.91% 26.16% 28.62%
Earnings before Tax (EBT) 1 -13.8 21.4 -23.3 97.9 117.9 -103.3 121.6 115.6 198.2 34.5 137.3 173.6 180 146.1 169.3
Net income 1 -7.3 13.9 -16.9 68.5 89 -76.6 95.5 83.1 147.7 43.4 111.1 131.3 147 112 129.8
Net margin -2.34% 4.48% -4.47% 17.66% 21.6% -18.22% 21.1% 16.66% 28.67% 8.42% 20.3% 23.12% 25.05% 19.36% 21.33%
EPS 2 -0.0800 0.1400 -0.1800 0.6900 0.8800 -0.7900 0.9500 0.8200 1.440 0.4200 1.054 1.266 1.335 1.138 1.330
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/11/22 5/4/22 8/4/22 11/1/22 2/6/23 5/3/23 8/1/23 10/31/23 2/7/24 5/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 620 483 376 1,119 1,549 1,997 2,795 3,648
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 137 218 233 323 362 579 759 943
ROE (net income / shareholders' equity) 6.62% 46.2% 14.9% 22.3% 12.7% 23.2% 23.9% 23.6%
ROA (Net income/ Total Assets) 3.22% 26.8% 9.76% 15.5% 8.89% 18% 47% -
Assets 1 1,150 1,520 918 999.7 2,810 2,437 1,417 -
Book Value Per Share 2 6.900 12.10 14.50 17.70 22.60 26.80 34.00 47.50
Cash Flow per Share 2 1.590 2.340 2.620 3.430 3.860 4.840 8.850 9.120
Capex 1 14.7 10.9 23.4 16.5 28.3 23.7 21.6 20.9
Capex / Sales 1.87% 1.04% 2.06% 1.11% 1.5% 1.07% 0.85% 0.7%
Announcement Date 2/4/20 2/4/21 2/11/22 2/6/23 2/7/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Neurocrine Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
136.7 USD
Average target price
157.8 USD
Spread / Average Target
+15.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+295.70% 8.12B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. Financials Neurocrine Biosciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW